Abstract:Enzymatic degradation of hyaluronan (HA), a key component of the extracellular matrix (ECM), can enhance tumor perfusion, improve delivery of chemotherapeutics, and enhance the effects of anti-tumor agents. Recombinant human hyaluronidase (rHuPH20), used clinically to facilitate local dispersion and absorption after subcutaneous delivery, is rapidly cleared from the blood after intravenous (IV) injection. To prolong serum residence time, a pegylated form of rHuPH20 was manufactured and shown to have anti-tumor activities in preclinical models (Thompson et al., Mol Cancer Ther 2010). PEGPH20 is a novel agent in early clinical trials to evaluate the safety and biological activities of hyaluronidase-based therapy. Twenty-three patients enrolled in two Phase 1 trials received IV PEGPH20 (0.5 - 50 μg/kg). To assess PEGPH20 PK, serial blood samples were drawn from patients, and plasma concentrations were measured using an in vitro hyaluronidase activity assay (LLOQ 0.3 U/mL). Plasma levels of HA catabolites were measured using a quantitative HPLC method to characterize PD. After a single 50 μg/kg dose, the PEGPH20 PK profile was well described by a two-compartment open model with a low initial distribution volume (V1 ∼ 60 mL/kg) and a terminal half-life of ∼2 days. Observed Cmax and AUC0-8hr values increased with increasing dose, suggesting linearity within the dose range. Model simulations derived from single-dose PK parameters were predictive of plasma concentrations from patients who received twice weekly dosing. There was no evidence for accumulation of PEGPH20 in the plasma after multiple dosing. Systemic concentrations of HA catabolites were measured to assess the PEGPH20 PD. HA levels detected 24 hours post administration increased with increasing dose of PEGPH20. Observed Cmax and AUC0-168hr values were also dose-dependent. After a 50 μg/kg bolus, HA concentrations increased 100-fold above baseline and persisted for >2 weeks. Repeat dosing with PEGPH20 resulted in sustained plasma concentrations of HA catabolites. Inter-patient variability in PD was notably greater than inter-patient variability in PK. Initial clinical PK/PD analysis indicates that systemic exposure after IV PEGPH20 is proportional to dose and is well described by a two-compartment PK model. Dose-dependent increases in HA catabolites provided a quantitative measure of PEGPH20 PD, consistent with the enzymatic activity of hyaluronidase. These data support continued evaluation of PEGPH20 to enhance delivery of anti-tumor agents via modification of the ECM. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 2672. doi:1538-7445.AM2012-2672

Human Spermatic Membrane-Bound Hyaluronidase (PH20) Promotes Cancer Cell (SW13) Growth

Hyaluronidase (PH-20) Promotes Breast Cancer Cell (MDA435) Growth

An Experimental Study of Human Membrane-Bound Hyaluronidase (PH-20) on Breast Cancer Cell (MDA231) Growth and Metastasis

Effects of Sodium Hyaluronate on Growth and Adhesion of Two Human Colorectal Cancer Cell Lines in Vitro

Human Hyaluronidase PH20 Potentiates the Antitumor Activities of Mesothelin-Specific CAR-T Cells Against Gastric Cancer

ANTITUMOR EFFECTS OF HUMAN IL-15 GENE MODIFIED LUNG CANCER CELL LINE

[Effects of Hepatocyte Growth Factor Gene Transfection on Adriamycin-Induced Apoptosis of Gastric Cancer Cells in Vitro].

[Effect of HAI-1 Over-Expression on in Vitro Growth and Migration/motility of SW620 Cells].

Study of Hyaluronan Binding Protein from Human Brain on Cancer Cells Proliferation

Effect of Steep Pulsed Electric Field on Proliferation, Viscoelasticity and Adhesion of Human Hepatoma SMMC-7721 Cells.

Experimental Study of Hyaluronic Acid Binding Protein on Human Cancer Cells Apoptosis

Breaching the Hyaluronan Barrier with PH20-Fc Facilitates Intratumoral Permeation and Enhances Antitumor Efficiency: A Comparative Investigation of Typical Therapeutic Agents in Different Nanoscales

Effects of Human Amelogenin Gene Transduction on Proliferation and Synthesis of Alkaline Phosphatase of Human Bone Marrow Stromal Cells

[Transfection of Human Hyperplasia Suppressor Gene and Hyperthermia Have a Synergistically Apoptotic Effect on Colon Cancer Cell HT-29 in Vitro].

Abstract 2672: Phase 1 pharmacokinetics (PK) & pharmacodynamics (PD) of PEGylated hyaluronidase PH20 (PEGPH20) in patients with solid tumors

[Human Hyperplasic Suppress Gene (hhsg) Could Increase the Chemotherapy Sensitivity of Human Tumor Cells in Vitro].

Effect of Adenovirus-Associated Virus Carrying Kringle 1 Domain of Hepatocyte Growth Factor Gene on the Growth of Human Prostatic Carcinoma Xenograft in Nude Mouse Bone

The effects of recombinant human hepatocyte growth factor on proliferation and VEGF expression of glioma cells

Effect of CTGF antisense oligodeoxynucleotide on the expression of MMP-9,VEGF and proliferation,invasion in pancreatic cancer cells

Hsg Provides Antitumor Efficacy On Hepatocellular Carcinoma Both In Vitro And In Vivo

Adenovirus-expressed human hyperplasia suppressor gene induces apoptosis in cancer cells.